Isoconazole nitrate, diflucortolone valerate.
1 g Travocort cream contains 10 mg isoconazole nitrate and 1 mg diflucortolone valerate in an easy-to-remove low fat base (o/w emulsion).
Broad-spectrum antimycotic with a corticoid additive.
Isoconazole nitrate is for use in the treatment of superficial fungal diseases of the skin.
It displays a very broad spectrum of antimicrobial action. It is effective against dermatophytes and yeasts, yeast-like fungi (including the causative organism of pityriasis versicolor) and moulds, as well as against the causative organism of erythrasma, and against gram-positive bacteria.
Diflucortolone valerate suppresses inflammation in inflammatory and allergic skin conditions and alleviates the subjective complaints such as itching, burning and pain.
Initial or interim treatment of those superficial fungal infections of the skin which are accompanied by highly inflammatory or eczematous skin conditions, e.g. in the regions of the hands, the interdigital spaces of the feet, and in the inguinal and genital regions.
Unless otherwise instructed by the doctor, Travocort should be applied twice daily to the affected areas of skin. In infections of the interdigital spaces it is advisable to place a strip of gauze smeared with Travocort between the toes or fingers. The treatment with Travocort must be terminated after regression of the inflammatory or eczematous skin condition, at the latest, however, after 2 weeks, and the therapy continued or followed up with the corticoid-free preparation Travogen.
This applies in particular for use in the inguinal and genital regions.
Tuberculous or syphilitic processes in the area to be treated; virus diseases (e.g. vaccinia, chickenpox, shingles).
As a general rule, topical preparations containing corticoids should not be applied during the first trimester of pregnancy. In particular, application to large areas of the body or for prolonged periods must be avoided.
Additional, specific therapy may be required in mixed bacterial infections caused by gram-negative organisms.
Travocort should not be allowed to come into contact with the eyes when being applied to the face.
If rosacea or perioral dermatitis is present, Travocort must not be applied to the face.
In general, Travocort is tolerated very well; signs of irritation or allergic reactions of the skin can occur in rare cases.
The following reactions may occur when Travocort is applied to large areas of the body (about 10% and more) and/or for long periods of time (more than 4 weeks): local concomitant symptoms such as atrophy of the skin, telangiectasia, striae and acneform changes of the skin, perioral dermatitis, increased growth of body hair (hypertrichosis), and systemic effects of the corticoid due to absorption.
Side effects cannot be excluded in neonates whose mothers have been treated extensively or for a prolonged period of time during pregnancy or while lactating (for example, reduced adrenocortical function, when applied during the last weeks of pregnancy).
D01AC20 - imidazoles/triazoles in combination with corticosteroids ; Belongs to the class of imidazole and triazole derivatives. Used in the topical treatment of fungal infection.